Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

TMC Life Research Inc

Neither a doctor nor a teaching hospital

Research payments

$1,951,190

467 payments

Through program year 2025, TMC Life Research Inc is reported as receiving $1,951,190 in research payments, across 467 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $339,454 113
2024 Research $481,459 188
2023 Research $328,891 57
2022 Research $282,295 72
2021 Research $335,688 14
2020 Research $13,718 4
2019 Research $169,686 19

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sumitomo Pharma America, Inc. $666,565 188 payments
  2. Abbott Laboratories $629,823 56 payments
  3. Astellas Pharma Global Development $204,840 81 payments
  4. Ventana Medical Systems, Inc. $183,203 22 payments
  5. Exeltis, USA Inc. $176,230 90 payments
  6. Myovant Sciences GmbH $73,149 18 payments
  7. Myovant Sciences Inc. $6,954 2 payments
  8. GlaxoSmithKline, LLC. $6,160 7 payments
  9. SCYNEXIS, Inc. $4,067 2 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $200 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $335,195 97 payments
  2. Alinity m HR HPV Specimen Collection Study from Women Undergoing Routine Cervical cancer Screening $296,476 10 payments
  3. A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms $204,840 81 payments
  4. Rd003109 $183,203 22 payments
  5. Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening $171,845 13 payments
  6. Alinity m HR HPV Specimen Collection Study from Women Referred to Colposcopy $157,497 29 payments
  7. A Phase 3 Singlearm Openlabel Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $143,696 35 payments
  8. Serene $98,529 20 payments
  9. A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $94,688 30 payments
  10. Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability of LPRI-424, 13 Cycles $76,086 22 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $4,067 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record